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ABSTRACT 
Genetically modified (GM) crops may bring new proteins with immunogenic and allergenic 
properties into the food and feed chains. The most commonly grown GM maize, MON810 
expresses a modified version of the insecticidal Cry1Ab protein originating in the soil 
bacterium Bacillus thuringiensis (Bt).  Immune reactions following inhalation of pollen and 
debris from such plants have been scarcely studied. We exposed BALB/c mice to purified 
Cry1Ab proteins and Cry1Ab-containing MON810 plant materials by intranasal installation. 
No anti-Cry1Ab antibodies were detected following exposure to the plant materials. Exposure 
to purified Cry1Ab resulted in specific anti-Cry1Ab IgG1 and IgE production, indicating 
inherent immunogenicity and allergenicity.  Mice exposed to leaf extracts from both MON810 
and unmodified maize demonstrated influx of lymphocytes and eosinophils in the broncho-
alveolar lavage, and increased cytokine release in mediastinal lymph node cells. The results 
indicate that the airway exposure to Cry1Ab proteins may be a route of practical relevance.  
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1. INTRODUCTION 
Genetically modified (GM) crops are created by direct transfer, insertion and ligation into the 
plant genome of a transgene, coding for a protein that may confer an advantageous trait, e.g. 
pest insect resistance, to the recipient plant (reviews in Traavik and Lim Li, 2007). As many 
GM crops bring new proteins into the food and feed chains, concerns have been raised about 
potential adverse effects in terms of toxicity (Hammond et al., 2013, Domingo and Gine 
Bordonaba, 2011), impaired nutrition value (EFSA, 2008) and undesirable immune responses 
(Finamore et al., 2008, Kroghsbo et al., 2008, Adel-Patient et al., 2011, EFSA, 2010, Taylor 
and Hefle, 2001, Bernstein et al., 2003). In predisposed individuals, immunogenic proteins 
(i.e. proteins that are able to induce specific humoral and/or cellular  immune responses) may 
be capable of stimulating a type-I hypersensitivity reaction through specific immunoglobulin 
(Ig) E responses, resulting in allergy against the protein (Poulsen and Hummelshoj, 2007).  
 
The assessment of potential immunogenicity and/or allergenicity of novel proteins expressed 
in a GM plant is a challenging task, as no single validated test or type of information exists to 
predict allergic or other immune responses against them (Kimber and Dearman, 2002, EFSA, 
2010). For ethical reasons, experimental sensitisation to potential allergens cannot be 
performed in humans, while epidemiological investigations have not been published so far. 
Current allergenicity assessment strategies, such as the pepsin resistance test and in vitro 
digestibility tests, the search for sequence and structural similarities between newly expressed 
proteins and known allergens, as well as in vitro IgE binding tests, have severe limitations 
(Bernstein et al., 2003, Guimaraes et al., 2010). Most importantly, in vitro testing cannot 
completely mimic the complex interaction between the many factors that are involved in the 
induction of an immune response. The EU scientific guidance document on the assessment of 
allergenicity of GM plants (EFSA, 2010) recognises the weight of evidence approach and 
case by case evaluation to be the most appropriate way of assessing the allergenicity of GM 
food and feed. Animal models, in particular, are mentioned as helpful to evaluate the potential 
of a newly expressed protein to sensitise and/or elicit allergic reactions, and to evaluate the 
immunogenic and/or adjuvant capacity of these proteins.  
 
The most commonly grown GM maize event, MON810, expresses an insecticidal Cry1Ab 
protein from a genome-inserted cry1Ab transgene originating in the soil bacterium Bacillus 
thuringiensis (Bt).The Cry1Ab protein is currently not considered an allergen in part based on 
the observation that specific IgE responses against Cry1Ab were not detected in exposed 
food-allergic humans (Nakajima et al., 2007). Moreover, it has been stated for Cry1Ab 
protoxin that there is no sequence similarity to known allergens (Randhawa et al., 2011), and 
the protein is rapidly digested in simulated gastric and intestinal fluids (EFSA, 2009). 
However, sequence similarity, protein source and digestibility alone cannot predict 
allergenicity. Several studies in mammals and fish have reported effects on the immune 
system after feeding of MON810-containing diets, including elevated levels of allergic and 
inflammatory associated cytokines in serum and altered percentage of B and T cells in the gut 
(Finamore et al., 2008) and a changed proportion of ileal B cells and macrophages (Walsh et 
al., 2011). Assessments of potential Cry1Ab immunogenicity and/or allergenicity have mostly 
been performed with purified protein isolated from the naturally occurring Bt spore Cry(stal) 
inclusions, or with a version produced in E. coli that is trypsinised to mimic the activated 
toxin expressed in GM plants. The many important structural and contextual differences 
between bacterial and plant Cry1Ab may, however, make extrapolations inadequate, and may 
have led to irrelevant conclusions.  In the Bt bacterium, Cry1Ab is expressed as a protoxin 
that must be activated by enzymatic cleavage in the lepidopteran gut to obtain its toxicity. The 
MON810 transgene, on the other hand, encodes only the N-terminal half of the protoxin. 
Hence it expresses an already activated version of the Cry1Ab toxin, which is probably 
structurally and immunogenically different from the Bt protoxin (Guerrero et al., 2004, 
Guerrero et al., 2007, Kitami et al., 2011).  Furthermore, transgenic insertions into a maize 
genome may cause a complex recombination event resulting in expression of “new” 
unanticipated proteins (Rosati et al., 2008). The different origins of the Cry1Ab protein 
(bacterium- or plant-expressed), as well as the specific version (protoxin, toxin, size, 
molecular conformation etc.) or context (purified bacterial, part of plant cell or tissue), thus 
prerequisite careful consideration and interpretation. 
 
Although the mucous membranes of the respiratory and gastro-intestinal tracts may be the 
most important portals of exposure (Vazquez-Padron et al., 2000, Kitami et al., 2011) little 
information exist on the potential immune effects after airway exposure to the Cry1Ab 
proteins.  Inhalation of pollen and plant debris may be a realistic exposure route for humans 
and domestic as well as wildlife animals in the fields, and also of workers during processing 
of food and feed. To our knowledge, airway exposure to adequate plant Cry1Ab proteins has 
not yet been investigated. Purified Cry1A protoxins and trypsin activated toxins have 
demonstrated specific humoral as well as cellular anti Cry1A immune responses after 
intranasal administration in mice (Guerrero et al., 2004, Guerrero et al., 2007). The same 
authors emphasized that the immune responses after intranasal exposure were unique, and 
suggested that binding of the lectin motifs of Cry proteins to the lectin binding receptors in 
nasal-associated lymphoid tissue (NALT) might contribute to that (Takata et al., 2000). The 
immunological potential of airway exposure to Cry1Ab-containing feed debris was directly 
illustrated, although unintended, when control fed and Cry1Ab-containing rice fed rats kept in 
the same room all developed Cry1Ab specific antibodies (Kroghsbo et al., 2008). In humans, 
Cry1Ab specific antibodies have been detected after occupational inhalation of Bt-based 
insecticidal sprayings (Bernstein et al., 1999, Doekes et al., 2004).  Studies like these indicate 
that specific immune responses may be induced after inhalation of Cry1Ab proteins.   
Given the expansion of cultivation areas for cry-transgenic maize varieties, the current 
knowledge gaps concerning immunogenicity and allergenicity of Cry1Ab proteins in general, 
and inhalation of such proteins in particular, warrants further research.  We hypothesized that 
airway exposure to Cry1Ab-expressing plant materials may induce immunological reactions. 
Since the origin/version/context of the Cry1Ab protein may give subtle structural 
modifications and thus affect the immune reactions, we investigated the various versions of 
the Cry1Ab protein to elicit immune and/or allergic responses in mice after intranasal 
exposure to 1) Cry1Ab protoxin, 2) trypsinised protoxin Cry1Ab (trypCry1Ab), 3) MON810 
pollen and 4) MON810 leaf extract.   
2. MATERIALS AND METHODS 
2.1. Animals 
Five to six-week old female BALB/c mice (Charles River, Sulzfeld, Germany) were allowed 
to rest for one week. The mice were randomly allocated to groups (8 –10 mice per group) and 
housed 3 – 5 animals together in cages with Nestpack bedding (Datesand Ltd, Manchester, 
UK). Pelleted Teklad Global 18% protein rodent diet 2018 (Harlan Laboratories, Madison, 
Wisconsin, USA) and tap water were given ad libitum. The mice were exposed to a 12/12 
hour light/dark cycle, room temperature of 21 +/- 2 C and 55 +/- 10 % humidity. The 
experiments were performed in conformity with laws and regulations for live animals, and 
approval was given by the North-West University Office of Ethics Committee (Ethical 
approval reference: NWU-00025-10-A3 Potchefstroom) and by the Norwegian Animal 
Research Authority under the Ministry of Agriculture (reference FOTS 4050) for experiment 
1 and 2 (described below), respectively.  
 
2.2. Experiments 
Experiment 1 was conducted at North-West University (NWU) in Potchefstroom, South 
Africa, in 2011, while experiment 2 was performed at the Norwegian Institute of Public 
Health (NIPH), Oslo in 2012. Although the two experiments were not supposed to be 
replicates (different origin/versions of the Cry1Ab protein were tested), the experimental 
conditions were kept as similar as possible (otherwise stated) and performed by the same 
investigator (MA).  
 
 
2.3. Experimental protocol 
The mice were anaesthetised and exposed intranasally (i.n.) to 35 µL of test solutions on days 
0, 1, 2, and booster i.n. on days 21, 22 and 23, and the experiments were terminated on day 26 
(Figure 1). A 100 µl blood sample was collected from vena saphena lateralis prior to the 
exposures on days 0 and 21. The mice were exsanguinated by heart puncture under 
anaesthesia on day 26, and blood and 3 x 0.8 mL bronco-alveolar lavage fluid (BALF) were 
collected as previously described by Samuelsen et al. (2009). BALF samples were kept on ice 
until processing. In experiment 2, MLNs were located according to Van den Broeck et al. 
(2006), excised, and single cell suspensions were prepared as described by Hansen et al. 
(2011).   
 
2.4. Cry1Ab protein  
Purified Cry1Ab protoxin isolated from Bacillus thuringiensis spores, prepared in PBS (pH 
7.4) and lyophilised, was purchased from Abraxis via Analytical Solutions (Banbury, South 
Africa). Trypsinised Cry1Ab (trypCry1Ab) protein was purchased from Case Western 
Reserve University, (Ohio, USA, Dr. Marianne Carey). The origin of the cry1Ab gene 
inserted in E. coli was the Bt kurstaki HD-1 strain. The inclusion bodies were solubilized at 
pH 10.5 in the presence of a reducing agent and the precipitated protoxins were digested by 
commercial bovine trypsin and subsequently purified by ion exchange HPLC. The relevant 
fractions were analysed by gel filtration, HPLC and SDS-PAGE, desalted and lyophilized (M. 
Carey, personal communication). The protein preparations were dissolved in a sterile 
physiological buffer (HBSS or PBS). The total doses of protoxin Cry1Ab and trypCry1Ab 
were 60 and 16.5 µg per mouse, respectively.  
 
2.5. Maize plant material 
The maize event MON810 (cultivar DKC78-15B) and its non-GM conventional counterpart 
(cultivar CRN 3505) were grown under identical conditions in pots in a greenhouse at NWU. 
The presence of Cry1Ab in MON810 plants was confirmed with the QuickStix kit for Cry1Ab 
corn leaf & seed (Envirologix, Portland, Maine, USA).  On days 0, 1, and 2 of the experiment, 
individual plant flowers from the two cultivars were carefully enclosed in plastic bags and 
shaken to dislodge pollen from flowers 2-3 hours before exposure to mice. After sieving twice 
to remove fragments other than pollen, 5 mg pollen was suspended in 350 µl sterile HBSS 
less than 1 hour before exposure. Additional pollen was frozen immediately and kept at minus 
80 C until exposures on day 21, 22 and 23. Frozen pollen was thawed in room temperature 2-
3 hours before exposure to mice and liquefied as described above.  
 
For leaf extract preparation, whole leaves were collected from greenhouse-cultivated 
MON810 (cultivar 6Q-308Bt) and non-GM (cultivar 6Q-121) maize plants at NWU. The 
leaves were enclosed in wet paper, sent by airmail to Norway. At arrival, the leaves were cut 
into 1 - 2 cm long pieces before manual grinding using a mortar and pestle. Ten ml HBSS was 
added to 1 gram of ground leaves and left overnight at 4 °C. After centrifugation at 2000 rpm 
for 5 min, the supernatant was collected and frozen at -18 until exposure.  
 
The content of plant expressed Cry1Ab in both pollen suspension and leaf extract were 
determined using a semi-quantitative ELISA kit (Agdia, Elkhart, Indiana, USA) following 
manufacturer instructions. Standard curves were obtained using progressive dilutions of a 
purified trypCry1Ab solution, ranging from 0.03 – 0.96 ng/µl and 3 – 96 ng/µL for the 
quantification of Cry1Ab in pollen and leaves respectively.  
 
2.6. Anaesthetics 
At NWU, an initial dose of 1.4 mL of Halothane (SafeLine Pharmaceuticals (Pty) Ltd, South 
Africa) was added to an inhalation chamber, and the mice were kept individually in the 
chambers until sedated. A supplementary dose of 0.4 ml of Halothane was then added once 
the sedative effect declined. At NIPH, 3.5 % Isofluran gas (Isoba vet; Intervet/Schering-
Plough Animal Health, Lysaker, Norway) was administered in surgical O2 in an inhalation 
chamber until sedation. 
 
2.7. Intranasal exposure 
Each individual mouse was put on its back, as droplets of the test solution were applied with a 
pipette onto the left and right nostril repeatedly until the complete volume of 35 µL was taken 
up. 
 
2.8. Detection of endotoxin in test solutions 
Endotoxin levels were measured in the pollen suspension (0.131 EU/mL in both MON810 
and non-GM), leaf extracts (0.130  and 0.129 EU/mL for MON810 and non-GM, 
respectively) and the trypCry1Ab solution (0.046 EU/mL) using ToxinSensor 
TM
 
Chromogenic LAL endotoxin Assay kit (GenScript, Piscataway, New Jersey, USA) according 
to the manufacturers’ description.  
2.9. Detection of Cry1Ab-Specific Antibodies 
In-house enzyme-linked immunosorbent assay (ELISA) protocols were established to detect 
specific anti-Cry1Ab IgG1, IgG2a and IgE in mouse sera. For the IgG1 assay, microtiter 96-
well plates (Maxisorp, Nunc-Immuno Plate, Thermo Fisher Scientific, Roskilde, Denmark) 
were coated with 2ng/µL purified trypCry1Ab protein  per well and incubated for 1 hour at 
room temperature (RT) and then overnight at 4 C. Plates were washed with 50 mM Tris/HCl 
buffer pH8 with 0.05 % Tween 20 (Tris/Tween) and incubated with blocking solution (5 % 
skimmed milk powder (Fluka Analytical, Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany) in phosphate buffered saline (PBS)) for 1 hour at room temperature (RT). After 
subsequent washing, diluted sera (1:50) were added and plates were incubated for 1 hour at 
RT and again overnight at 4 C. The plates were washed, 200 ng biotinylated rat anti-mouse 
IgG1 (Experimental Immunology Unit, University of Louvain, Belgium) was added per well 
and plates were incubated for 1 hour at RT. After subsequent washing, poly-HRP-streptavidin 
(Thermo-Scientific, Pierce Biotechnology Inc., Rockford, IL, USA) diluted 1:40000 was 
added and incubated for 1 hour at RT. The plates were washed and colour development was 
obtained by adding stabilized chromogen TBM (Invitrogen). The reaction was stopped with 
2N H2SO4 solution, after incubation in darkness for a maximum of 15 minutes.  
 
Considering the small relative amounts of IgE compared to other classes of Igs, competitive 
displacement of IgE by the latter must be avoided. Therefore, we used anti-mouse IgE 
antibodies as capture antibody. Microtiter 96-well plates with 96 wells were coated with 200 
ng rat anti mouse IgE antibodies (clone LO-ME-3, Experimental Immunology Unit, 
University of Louvain, Belgium,) per well, incubated for 1 hour at RT and then overnight at 4 
C. Subsequently, the plates were washed with Tris/Tween and blocked with 5% skimmed 
milk in PBS for 1 hour at RT. After subsequent washing, diluted sera (1:10) were added and 
plates were incubated for 1 hour at RT and then again over night at 4 C. The following day 
plates were washed, 300 ng trypCry1Ab were added to each well and incubated for 1 hour at 
RT. After subsequent washing, 300 ng biotinylated rabbit anti mouse Cry1Ab antibody 
(Abraxis, Warminster, Pennsylvania, USA) were added per well as detection antibody and 
plates were incubated for 1 hour at RT. Plates were washed and detection was performed with 
poly-HRP-streptavidin and stabilized chromogen TBM as described above. The reaction was 
stopped with 2N H2SO4 solution after incubation in darkness for a maximum of 15 minutes.  
 
The relative amount of specific IgG2a is apparently small, and a Cry1Ab-specific IgG2a 
ELISA protocol was established using the same reasoning as for detection of Cry1Ab-specific 
IgE. Microtiter plates with 96 wells were coated with 200 ng biotinylated rat anti mouse 
IgG2a antibodies (clone R19-15, BD Biosciences Pharmingen, San Diego, California, USA) 
per well, and the protocol for Cry1Ab-specific IgE detection was subsequently followed as 
described above. To accelerate the reactivity of each step, incubations were performed at 37 
C for the detection of specific anti-Cry1Ab IgG2a. 
 
Standard curves were made from duplicates of diluted serum pools from mice immunized 
with trypCry1Ab and Al(OH)3,  and included for all antibody assays on each plate. As the 
amount of specific IgG1, IgE and IgG2a in the standards is unknown, the levels are presented 
as arbitrary units (AU). Absorbance was measured at 450 nm on a BioTek Elx808 
Absorbance Microplate reader with the Gen5™ Microplate Data Collection & Analysis 
Software (BioTek
®
 Instruments, Inc., Winooski, Vermont, USA). 
2.10. Cytokine analyses  
Cytokine levels in BALF and in supernates from MLN cells were determined by Cytometric 
Bead Array (CBA) flex set kit from BD Biosciences (San Diego, California, USA). Beads 
dyed with fluorescence red and covalently coupled to antibodies that capture specific 
cytokines, allow simultaneous quantification of several cytokines. IL-5, IL-10, IFN, TNF 
and MCP-1 were measured in BALF from both experiments. IL-10, IFN, IL-4, IL-13 and IL-
17 were determined in the supernates from MLN cells stimulated with 172 µg/mL 
trypCry1Ab and incubated at 37 C for 120 hours, in experiment 2. 
 
2.11. Differential counts 
Cells (125 000 cells/mL) from all three BALF collections from each individual mouse were 
spun down on to cytoslides using a cytocentrifuge (Shandon Scientific Ltd., Astmoor, 
Runcorn, UK) at 70 g for 6 minutes, and stained with the Hemacolour rapid staining 
according to the manufacturer’s protocol (Merc KGaA, Darmstadt, Germany). A total number 
of 200 cells were counted on each slide in a light microscope (Axioplan2, Zeiss, Göttingen, 
Germany) at 100x magnification, differentiating macrophages, eosinophils, neutrophils, 
lymphocytes and epithelial cells based on their morphological characteristics. Cell differential 
counts for all animals were performed blindly by the same investigator (MA).  
 
2.12. Statistical analyses 
Statistical analyses were performed using SigmaPlot 12.3 and Minitab 16 Statistical software. 
All normally distributed parameters with comparable variances were tested by one-way 
ANOVA. When necessary, data were log10 transformed to obtain normal distribution and 
comparable variances. In the case of significant overall differences, pair-wise comparisons 
between treatment and control or between pairs of treatments were performed with the 
Dunnets post hoc test. Data that could not be transformed to normal distribution and 
comparable variances were tested with the non-parametric Kruskal-Wallis test, using Mann-
Whitney post hoc tests for pair-wise comparisons between treatments versus control or 
between pairs of treatments. Differences between outcomes were considered significant when 
p-values were < 0.05.  
 
  
3. RESULTS 
3.1. Cry1Ab exposure dose 
Based on the measured concentrations (Table 1) the calculated total dose of Cry1Ab given per 
mice exposed to pollen or leaf extracts was 0.02 µg and 12.86 µg, respectively. Non-GM 
pollen and leaves had no detectable content of Cry1Ab protein.  
 
3.2. Serum Cry1Ab-specific antibodies 
Cry1Ab-specific antibodies were analysed in sera collected prior to the intranasal exposures 
on days 0 and 21, and at termination on day 26. Cry1Ab-specific antibodies were not detected 
on day 0. Cry1Ab-specific IgG1 was elevated on day 21 in mice exposed to both Cry1Ab 
protoxin and trypCry1Ab compared to controls (data not shown). On day 26, mice exposed to 
Cry1Ab protoxin, but not maize pollen, had significantly higher serum levels of both Cry1Ab-
specific IgE and IgG1, and a tendency towards a higher serum level of Cry1Ab-specific 
IgG2a, compared to the control group (Figure 2a, b, c). Furthermore, mice exposed to 
trypCry1Ab protein, but not maize leaf extracts, had elevated serum level of Cry1Ab-specific 
IgG1 and Cry1Ab-specific IgE, on day 26 (figure 2 d, e, f). Cry1Ab-specific IgG2a levels 
were not determined on day 0 and 21 due to limited amounts of serum, and the levels on day 
26 did not significantly differ in mice from either group.    
 
3.3. Cytokine levels in BALF 
IL-5, IL-17, MCP-1, TNF and IFN cytokine levels determined in BALF collected on day 
26 were very low (figure 3). Although statistically significant differences between the groups 
were observed, levels of cytokines in mice exposed to Cry1Ab protoxin or MON810 pollen 
were not significantly different from those exposed to the non-GM pollen. Cytokine levels in 
BALF collected on day 26 after exposure of mice to trypCry1Ab and maize leaf extracts were 
below the detection limit irrespective of the exposure scheme (data not shown). 
 
3.4. Cell differential counts  
The percentage of neutrophils, macrophages, lymphocytes and eosinophils were determined 
in BALF from mice exposed to trypCry1Ab and maize leaf extracts. Mice exposed to 
MON810 leaf extract had a significantly higher percentage of lymphocytes and eosinophils, 
and significantly lower percentage of macrophages, than mice in the control group (Figure 4). 
However, these numbers were not significantly different from what was observed in mice 
exposed to the non-GM leaf extract. The percentage of neutrophils was not different between 
any groups of mice irrespective of exposure scheme.  
 
3.5. Ex vivo cytokine secretion from MLN cells 
Cytokines were measured in supernates from MLN cells collected on day 26 and stimulated 
with trypCry1Ab. IL-10 was significantly elevated in mice exposed to MON810 leaf extract 
compared to mice exposed to non-GM extract, and compared to control mice (Figure 5a). 
Furthermore, mice exposed to MON810 leaf extract had significantly higher levels of IL-4, 
IL-13, IFN, and IL-17 compared to mice in the PBS-control group, however the levels were 
not significantly different from mice exposed to non-GM leaf extract (figure 5).   
4. DISCUSSION 
The MON810 plant material did not elicit humoral immune responses in mice after airway 
exposure. However, the production of specific IgG1 against the two purified protein versions 
indicates that Cry1Ab protein as such is capable of provoking immunogenic responses, and 
the production of specific IgE further indicate the capability of Cry1Ab to induce pro-allergic 
responses, in mammals. In the field, the airway exposure of Cry1Ab proteins (e.g. trough 
pollen and dust) is a highly relevant route of exposure and our results therefore warrants 
further studies. Our findings are in agreement with previous investigations showing 
immunogenic responses after Cry1Ab administration through other routes. For example, 
Cry1Ab-specific IgG, IgE and IgG2a antibody response were detected in BALB/c mice 
immunised intraperitoneally (i.p.) with the protoxin Cry1Ab, however this was not the case 
after intragastric (i.g.) administration (Adel-Patient et al., 2011). The authors did not, like us, 
detect specific antibody responses after immunisation with a protein extract from MON810 
maize, neither via the i.p. nor the i.g. route. On the other hand, our results are only partly in 
line with the findings of Guerrero et al. (2004). While an i.p. immunisation with a total dose 
of 150 µg purified protoxin Cry1Ab (produced in recombinant E.coli; 133 kDa) resulted in a 
strong specific IgG antibody response in BALB/c mice, i.n. immunisations with the same 
dose gave no such response.  Furthermore, 150 µg of toxin Cry1Ab (trypsinised protoxin; 70 
kDa) induced a strong specific IgG response after both the i.p. and i.n. immunisation route.  
 
The precise measurement of Cry1Ab concentrations in plant material has been proven to be a 
difficult task, with significant inter-laboratory differences (Szekacs et al., 2012) and huge 
variations in in concentrations reported and methods used. Furthermore the expression levels 
of Cry1Ab as well as the whole proteome of a given GM plant may vary considerably when it 
is grown under different environmental conditions (Agapito-Tenfen et al., 2013).  The 
calculated Cry1Ab content in our plant material was based on values form an adjusted semi-
quantitative assay and is thus not absolutely, but reflects a relative difference in the Cry1Ab 
content in different parts of the plant, suggesting that leaves contain approximately 90 times 
more Cry1Ab than pollen. Nevertheless, mice exposed to both plant materials received a 
considerably lower dose of Cry-proteins compared to those exposed to purified protein 
solutions, which could, at least in part, explain the lack of humoral responses against the plant 
Cry1Ab. On the other hand, immunisation with low doses of allergens has been shown to 
induce higher IgE production than high doses (Arps et al., 1998, Hansen et al., 2011), i.e. not 
supporting a simple positive dose-response relationship. This was also the case in a study by 
Adel-Patient et al. (2011), where 1 µg protoxin Cry1Ab induced a specific IgE response, 
while the dose of 100 µg did not. In addition, structural differences between the Cry1Ab 
proteins we used in our four treatments may be accountable for the difference in immune 
responses. The trypsin activation of the protein produced in E. coli is supposed to give a 
Cry1Ab that is similar to the activated version expressed in plants, although the degree of 
similarity has not been confirmed. Also post-translational differences could explain the 
difference in immune response between purified protein and plant material preparations, as 
suggested by Prescott et al. (2005). It was demonstrated in a mouse model that transgenic 
expression of the bean alpha-amylase inhibitor-1 (αAI) in peas led to the synthesis of a 
protein variant with altered immunogenicity. However, these findings could not be 
reproduced by Lee et al. (2013). Whether the dissimilar responses to plant and purified 
protein preparations are due to discrepancy in doses or structural differences can however not 
be answered by the present study.  
 
To our knowledge, a Cry1Ab specific IgE response has not previously been demonstrated 
after airway exposure to Cry1Ab proteins. Since the amount of specific IgE antibodies in 
general are relatively low compared  to other classes of immunoglobulins, and thus vulnerable 
to be outcompeted by immunoglobulins in abundance (Ladics et al., 2010), our sandwich 
ELISA design trapped Cry1Ab specific IgE on the well surface by coating microtiter plates 
with anti-IgE monoclonal antibodies, before incubating with trypCry1Ab protein and 
biotinylated anti-Cry1Ab as the detection antibody. The use of the trypsinised version of the 
Cry1Ab protein in the assay could theoretically result in lack of detection of the fraction of 
specific antibodies towards epitopes present on the protoxin or the plant version. However, 
previous studies suggest that most epitopes are on the N-terminal present on both protoxin 
and trypsinised versions of Cry1Ab (Guerrero et al., 2004), and our data demonstrate the 
presence of Cry-specific IgE responses in animals treated with both protein versions.  
 
It should be noted that the clinical relevance of the detected specific IgE was not evaluated. 
The inbred BALB/c is an “allergy prone” mouse strain that easily adopt the allergy-associated 
Th2 response pathway.  The strain has been employed in previous allergy models and usually 
requires an adjuvant to elicit an allergic response (Nygaard et al., 2005). Here, a clear specific 
IgE response against both protoxin and trypsinised Cry1Ab was elicited even without an 
adjuvant, suggesting that genetically predisposed (or atopic) subjects may develop Cry1Ab 
IgE antibody response after airway exposure. Furthermore it is important to recognise that the 
model is optimised to induce allergy as the protocol with three consecutive immunisations and 
thereafter three booster immunisations is more likely to provoke IgE responses.  
 
Because we observed a specific antibody response against the trypsinised Cry1Ab protein we 
might also anticipate an effect on cell influx in lungs and cytokine release from MLN cells 
from mice exposed to the trypCry1Ab protein compared to controls. However, these 
parameters were not significantly altered by trypCry1Ab.  Interestingly, a significant influx of 
lymphocytes and eosinophils in the broncho-alveolar lavage fluid were evident in the 
MON810 leaf extract exposed mice compared to controls, and also the cytokine release of 
IL10, IFN, IL4, IL-13 and IL-17 were higher in MLN cells from the MON810 leaf exposed 
mice. When MLN cells were stimulated in vitro with the trypCry1Ab protein, cytokine release 
was induced only in MON810 treated mice, indicating a specific response to the Cry1Ab 
epitopes, i.e. suggesting immunogenicity of Cry1Ab protein of plant origin. The increase of 
cytokines both related to Tregs (IL-10), Th2 (IL-4 and IL-13), Th1 (IFN) and Th17 (IL-17) 
cells, suggest a general immune stimulation rather than skewing of the immune response in a 
particular direction. In agreement, the antibody response towards the Cry1Ab induced by 
protoxin and trypCry1A were both associated with Th1 and Th2 associated antibody classes 
(IgG2a, and IgE and IgG1, respectively). However, neither the cell influx nor the cytokine 
levels (with IL-10 as the only exception) were significantly different from the non-GM 
exposed mice, suggesting that the local immune response was elicited in response to the plant 
material as such, and not related to the Cry1Ab protein.  
 
It has previously been demonstrated that immunisation dose, as well as sex and age, highly 
influence the allergy outcome (Hansen et al., 2011). The immunogenic and allergenic effects 
seen in prime aged females (6-11weeks old) included in the present experiment and in males 
(10-x weeks old) in (Guerrero et al., 2004)  indicate that Cry1Ab proteins could affect the 
mature immune system. Little is known, however, concerning the impact of these proteins on 
vulnerable groups. Finamore et al. (2008) reported that the immune systems of young and old 
rats were more affected by Cry1Ab containing feed, than prime aged individuals. It would 
therefore be reasonable to assume that the present findings would be of even greater 
importance in vulnerable age groups or in hypersensitive individuals.  
 
Although no Cry protein immunogenicity could be observed at the present dose of MON810 
pollen or leaf extract, the specific antibody response against the purified Cry1Ab protoxin and 
toxin preparations demonstrates the principle that these proteins may affect the immune 
system, i.e. act as immunogens, after intranasal administration. The elicitation of specific IgE 
antibodies indicates allergenicity of the purified Cry1Ab proteins. However, this was not 
observed after exposure to (lower doses of) Cry1Ab in plant materials. Notably, the observed 
immune responses were elicited in the absence of an adjuvant. Given the importance of Bt-
transgenic maize as food and feed across the world, a considerable number of individuals may 
be exposed to Cry1Ab by inhalation, in the field as well as along the food/feed chain. Thus, 
our results warrant further clarification and testing, both in animal models and in humans, 
including emphasis on vulnerable age groups and hypersensitive individuals.  
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Table 1. Total exposure doses of Cry1Ab in MON810 pollen and leaves per mouse.  
Source Cry1Ab (µg/mg) 
 
Plant material (mg) 
per mouse 
Total dose Cry1Ab (µg) 
per mouse 
MON810 pollen 0.00692 3
a
 0.02 
MON810 leaf 0.61251 21
b
 12.86 
a 
Exposure 6 days of 500 µg pollen each day.  
b 
Exposure 6 days of 3.5 mg leaves (in extract form) each day 
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Figure 1. Experimental protocol. Mice were intranasally (i.n.) immunised with Cry1Ab protoxin, 
MON810 pollen and non-GM pollen (experiment 1), and trypsinised Cry1Ab (trypCry1Ab), MON810 
leaf extract and non-GM leaf extract (experiment 2) on days 0, 1, 2, and boostered i.n. with the 
equivalent test materials on days 21, 22, 23. Blood samples were collected on day 0 and 21, and blood, 
broncho-alveolar lavage fluids (BALF) and mediastinal lymph nodes (MLN) were collected at 
termination on day 26.  
 
Figure 2. Cry1Ab specific IgG1 (a), IgE (b) and IgG2a (c) in serum after intranasal immunisation and 
booster of mice to Cry1Ab protoxin and fresh MON810 maize pollen and non-GM pollen on days 0, 
1, 2, 3, 21, 22 and 23. Cry1Ab specific IgG1 (d), IgE (e) and IgG2a (d) in serum after intranasal 
immunisation and booster of mice to trypsinised Cry1Ab and MON810 leaf extract and non-GM leaf 
extracts on days 0, 1, 2, 3, 21, 22 and 23. Asterisks (*) denote groups that are significantly different 
(p<0.05) from control group exposed to physiological buffer only.  
 
Figure 3. Cytokine IL-5 (a), MCP-1 (b), IL-17 (c), TNF (d) and IFN (e) levels in bronco-alveolar 
lavage fluid (BALF) collected on day 26 after intranasal exposure of mice to Cry1Ab protoxin and 
fresh maize pollen on days 0, 1, 2, 21, 22 and 23. Each circle represents one individual animal, and 
bars represent group medians. The dotted lines indicate the lower quantitative detection limit of the 
assays. Asterisks (*) denote groups that are significantly different (p < 0.05) from the control group 
(CTRL) exposed to physiological buffer only.  
 
Figure 4. Percentages (%) of macrophages (a), neutrophils (b), lymphocytes (c) and eosinophils (d) in 
the bronco-alveolar lavage fluid (BALF) collected on day 26 after intranasal exposure of mice to 
trypsinised Cry1Ab (trypCry1Ab), or leaf extracts from the genetically modified maize event 
MON810 and its conventional counterpart (non-GM) on days 0, 1, 2, 21, 22 and 23. Bars represent 
group medians, circles represent one individual animal. Asterisks (*) denote groups that are 
significantly different (p < 0.05) from the control group exposed to physiological buffer only. 
 
Figure 5. Cytokine IL-10 (a), IFN (b), IL-4 (c), IL-13 (d) and IL-17 (e) secretion (pg/mL) from 
mediastinal lymph node (MLN) cells collected on day 26 after intranasal exposure of mice to 
trypsinised Cry1Ab (trypCry1Ab), or leaf extracts from the genetically modified maize event 
MON810 or its conventional counterpart (non-GM) on days 0, 1, 2, 21, 22 and 23. Each circle 
represents one individual animal, and bars represent group medians. The dotted lines indicate the 
lower quantitative detection limit of the assays. Asterisks (*) denote groups that are significantly 
different (p < 0.05) from the control group exposed to physiological buffer only 
 
 
 
 
 
 
